Search results
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 10 hours agoPatent expirations pose a significant threat to Regeneron's revenue, as key products may face...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 1 day agoTotal collaboration revenues missed the Zacks Consensus Estimate of $1.32 billion. Sanofi’s...
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoSanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS,...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 1 day agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global ...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 3 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Board trying to lower drug costs urges Marylanders to help ‘fill in’ info gaps
Maryland Matters via Yahoo News· 3 days agoThe Prescription Drug Affordability Board is seeking feedback from patients, physicians and manufactures to provide context and first-hand experience about trying to afford medications for certain ...
Moderna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall By Investing.com
Investing.com· 1 day agoModerna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall
Regeneron records mixed results for Q1 as Eylea revenues fall
Crain's New York Business· 17 hours agoThe slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 7 days agoMerck slightly raised the upper end of its 2024 revenue guidance range from $62.7-$64.2 billion to...